Glycoside dual-cleavage linkers for antibody-drug conjugates
The present disclosure provides antibody-drug conjugate structures, which include a cleavable linker that links the antibody to the drug and has a first enzymatically cleavable moiety and a second enzymatically cleavable moiety which includes a glycoside selected from a galactoside, a glucoside, a mannoside, a fucoside, O-GlcNAc, and O-GalNAc. The disclosure also encompasses compounds and methods for production of such conjugates, as well as methods of using the conjugates.
1. A conjugate comprising:
an antibody;
a drug; and
a cleavable linker that links the antibody to the drug and comprises a first enzymatically cleavable moiety and a second enzymatically cleavable moiety comprising a glycoside selected from the group consisting of a galactoside and a glucoside, and
wherein the conjugate is of formula (I):
wherein
Z is CR 4 or N;
X is O or NR 4 ;
R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
R 2 and R 3 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acyl amino, amino acyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, or R 2 and R 3 are optionally cyclically linked to form a 5 or 6-membered heterocyclyl;
each R 4 is independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acyl amino, amino acyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
each R 5 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl;
each R 6 is independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
k is an integer from 1 to 10;
R 7 comprises the second enzymatically cleavable moiety;
L 1 is a first linker;
L 2 is a second linker;
W 1 is a maytansine; and
W 2 is the antibody.
2. The conjugate of claim 1 , wherein:
k is 2; and
the conjugate is of formula (Ia):
3. The conjugate of claim 1 , wherein the second enzymatically cleavable moiety comprises a galactoside.
4. The conjugate of claim 1 , wherein the second enzymatically cleavable moiety comprises a glucoside.
5. The conjugate of claim 2 , wherein the conjugate is of formula (Ib):
6. The conjugate of claim 2 , wherein the conjugate is of formula (Ic):
7. The conjugate of claim 1 , wherein L 1 comprises:
-(T 1 -V 1 ) a -(T 2 -V 2 ) b -(T 3 -V 3 ) c -(T 4 -V 4 ) d -,
wherein
a, b, c and d are each independently 0 or 1;
T 1 , T 2 , T 3 and T 4 are each independently selected from a covalent bond, (C 1 -C 12 )alkyl, substituted (C 1 -C 12 )alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w , (PEG) n , (AA) p, —(CR 13 OH) m —, 4-amino-piperidine (4AP), an acetal group, a hydrazine, a disulfide, and an ester, wherein EDA is an ethylene diamine moiety, PEG is a polyethylene glycol, and AA is an amino acid residue or an amino acid analog, wherein each w is an integer from 1 to 20, each n is an integer from 1 to 30, each p is an integer from 1 to 20, and each m is an integer from 1 to 12;
V 1 , V 2 , V 3 and V 4 are each independently selected from the group consisting of a covalent bond, —CO—, —NR 15 —, —NR 15 (CH 2 ) q —, —NR 15 (C 6 H 4 )—, —CONR 15 —, —NR 15 CO—, —C(O)O—, —OC(O)—, —O—, —S—, —S(O)—, —SO 2 —, —SO 2 NR 15 —, —NR 15 SO 2 — and —P(O)OH—, wherein each q is an integer from 1 to 6;
each R 13 is independently selected from hydrogen, an alkyl, a substituted alkyl, an aryl, and a substituted aryl; and
each R 15 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.
8. The conjugate of claim 1 , wherein L 2 comprises:
-(T 5 -V 5 ) e -(T 6 -V 6 ) t -(T 7 -V 7 ) g -(T 8 -V 8 ) h -,
wherein
e, f, g and h are each independently 0 or 1;
T 5 , T 6 , T 7 and T 8 are each independently selected from a covalent bond, (C 1 -C 12 )alkyl, substituted (C 1 -C 12 )alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w , (PEG) n , (AA) p , —(CR 13 OH) m —, 4-amino-piperidine (4AP), an acetal group, a hydrazine, a disulfide, and an ester, wherein EDA is an ethylene diamine moiety, PEG is a polyethylene glycol, and AA is an amino acid residue or an amino acid analog, wherein each w is an integer from 1 to 20, each n is an integer from 1 to 30, each p is an integer from 1 to 20, and each m is an integer from 1 to 12;
V 5 , V 6 , V 7 and V 8 are each independently selected from the group consisting of a covalent bond, —CO—, —NR 15 —, —NR 15 (CH 2 ) q —, —NR 15 (C 6 H 4 )—, —CONR 15 —, —NR 15 CO—, —C(O)—, —OC(O)—, —O—, —S—, —S(O)—, —SO 2 —, —SO 2 NR 15 —, —NR 15 SO 2 — and —P(O)OH—, wherein each q is an integer from 1 to 6;
each R 13 is independently selected from hydrogen, an alkyl, a substituted alkyl, an aryl, and a substituted aryl; and
each R 15 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.
9. The conjugate of claim 7 , wherein:
T 1 is selected from a (C 1 -C 12 )alkyl and a substituted (C 1 -C 12 )alkyl;
T 2 , T 3 , and T 4 are each independently selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w , (PEG) n , (C 1 -C 12 )alkyl, substituted (C 1 -C 12 )alkyl, (AA) p , —(CR 13 OH) m —, 4-amino-piperidine (4AP), an acetal group, a hydrazine, and an ester; and
V 1 , V 2 , V 3 and V 4 are each independently selected from the group consisting of a covalent bond, —CO—, —NR 15 —, —NR 15 (CH 2 ) q —, —NR 15 (C 6 H 4 )—, —CONR 15 —, —NR 15 CO—, —C(O)O—, —OC(O)—, —O—, —S—,—S(O)—, —SO 2 —, —SO 2 NR 15 —, —NR 15 SO 2 —, and —P(O)OH—;
wherein:
(PEG) n is
where n is an integer from 1 to 30;
EDA is an ethylene diamine moiety having the following structure:
where y is an integer from 1 to 6 and r is 0 or 1;
4-amino-piperidine (4AP) is
each R 12 and R 15 is independently selected from hydrogen, an alkyl, a substituted alkyl, a polyethylene glycol moiety, an aryl and a substituted aryl, wherein any two adjacent R 12 groups may be cyclically linked to form a piperazinyl ring; and
R 13 is selected from hydrogen, an alkyl, a substituted alkyl, an aryl, and a substituted aryl.
10. The conjugate of claim 7 , wherein:
T 1 is (C 1 -C 12 )alkyl and V 1 is —CO—;
T 2 is an amino acid analog and V 2 is —NH—;
T 3 is (PEG) n and V 3 is —CO—; and
d is 0.
11. The conjugate of claim 8 , wherein:
T 5 is a covalent bond and V 5 is —CO—; and
f, g and h are 0.
12. The conjugate of claim 8 , wherein:
T 5 is a covalent bond and V 5 is —CONR 15 —;
T 6 is (C 1 -C 12 )alkyl and V 6 is —CO—; and
g and h are 0.
13. A pharmaceutical composition comprising:
a conjugate gate of claim 1 ; and
a pharmaceutically-acceptable excipient.
14. A method of administering a conjugate to a subject, the method comprising:
administering to a subject a conjugate of claim 1 .
15. A method of treating cancer in a subject, the method comprising:
administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising a conjugate of claim 1 , wherein the administering is effective to treat cancer in the subject.